Financials Median Technologies

Equities

Market Closed - Euronext Paris Other stock markets 11:35:01 2024-07-10 am EDT			5-day change	1st Jan Change
2.6 ^EUR	-3.35%		-0.38%	-45.26%

May. 22	Median: service contract with a major pharmaceutical company	CF
May. 21	Median Technologies Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	23.85	83.53	241.4	140.2	87.31	47.83	-	-
Enterprise Value (EV) ¹	23.85	82.79	218.9	136.9	87.31	67.05	87.05	96.06
P/E ratio	-2.98 x	-6.57 x	-12.5 x	-6.95 x	-3.8 x	-1.9 x	-2.1 x	-3.25 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	-	6.19 x	11.8 x	5.89 x	3.93 x	2 x	1.61 x	1.23 x
EV / Revenue	-	6.13 x	10.7 x	5.75 x	3.93 x	2.81 x	2.93 x	2.48 x
EV / EBITDA	-	-10.3 x	-20.1 x	-6.08 x	-4.03 x	-3.02 x	-4.18 x	-5.98 x
EV / FCF	-	-14.4 x	-20.6 x	-7.97 x	-4.06 x	-3.07 x	-4.18 x	-4.81 x
FCF Yield	-	-6.95%	-4.84%	-12.5%	-24.6%	-32.6%	-23.9%	-20.8%
Price to Book	-	-	-	-	-	-1.42 x	-0.76 x	-0.7 x
Nbr of stocks (in thousands)	12,106	12,106	15,437	15,775	18,382	18,395	-	-
Reference price ²	1.970	6.900	15.64	8.890	4.750	2.600	2.600	2.600
Announcement Date	4/14/20	4/8/21	4/21/22	4/20/23	4/25/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	13.5	20.5	23.8	22.23	23.89	29.72	38.75
EBITDA ¹	-	-8.012	-10.88	-22.51	-21.66	-22.21	-20.81	-16.07
EBIT ¹	-	-8.819	-11.57	-23.36	-23.12	-22.81	-21.79	-17.18
Operating Margin	-	-65.33%	-56.43%	-98.13%	-104%	-95.49%	-73.31%	-44.33%
Earnings before Tax (EBT) ¹	-	-	-	-	-22.98	-22	-24	-23.4
Net income ¹	-7.984	-12.8	-19.29	-20.21	-22.98	-24.2	-21.7	-19
Net margin	-	-94.83%	-94.11%	-84.93%	-103.4%	-101.3%	-73%	-49.04%
EPS ²	-0.6600	-1.050	-1.250	-1.280	-1.250	-1.367	-1.238	-0.8000
Free Cash Flow ¹	-	-5.752	-10.61	-17.18	-21.49	-21.83	-20.8	-19.97
FCF margin	-	-42.61%	-51.74%	-72.18%	-96.68%	-91.39%	-69.97%	-51.53%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	4/14/20	4/8/21	4/21/22	4/20/23	4/25/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	19.2	39.2	48.2
Net Cash position ¹	-	0.74	22.5	3.32	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-0.8657 x	-1.885 x	-3.002 x
Free Cash Flow ¹	-	-5.75	-10.6	-17.2	-21.5	-21.8	-20.8	-20
ROE (net income / shareholders' equity)	-	-	-	-	-	-	-	-
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	-	-	-	-	-	-1.830	-3.410	-3.710
Cash Flow per Share ²	-	-0.4500	-0.6500	-1.000	-1.100	-1.280	-1.060	-0.7000
Capex ¹	-	-	-	1.39	1.25	1.55	1.6	1.8
Capex / Sales	-	-	-	5.83%	5.64%	6.49%	5.38%	4.65%
Announcement Date	4/14/20	4/8/21	4/21/22	4/20/23	4/25/24	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.69 EUR

Average target price

16.92 EUR

Spread / Average Target

+529.18%

	1st Jan change	Capi.
MEDIAN TECHNOLOGIES	-45.26%	53.49M
THERMO FISHER SCIENTIFIC	+1.15%	203B
DANAHER CORPORATION	+4.69%	178B
INTUITIVE SURGICAL, INC.	+31.83%	157B
BOSTON SCIENTIFIC CORPORATION	+33.39%	112B
SIEMENS HEALTHINEERS AG	+2.21%	64.58B
EDWARDS LIFESCIENCES CORPORATION	+22.99%	56.33B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.03%	46.75B
AGILENT TECHNOLOGIES, INC.	-8.60%	36.59B
GE HEALTHCARE TECHNOLOGIES INC.	+2.35%	35.09B